Orphan drug designation applications personally decided as Director of the FDA's Office of Orphan Products Development, resulting in 200 orphan drugs reaching market.
Clients served through Cote Orphan Consulting, Dr. Cote's first boutique consultancy, acquired by IQVIA.
Clients served by Only Orphans Cote, applying the same standard from a dedicated boutique team.
Founded by Dr. Cote to develop a topical therapy for high grade dysplasia, an official population of 90,000+ US patients. The program is now headed to the clinic.
With a focus on successful outcomes, your program will be managed by a highly professional team of specialists guided by Dr. Cote's unique regulatory experience.
Founder & CEO
Founder & CEO
Dr. Timothy R. Coté, MD MPH, is a renowned national regulatory expert in orphan drug regulatory affairs. He is founder and CEO at Only Orphans Cote with offices in Cambridge MA and Washington DC, leading a select team of experts in rare diseases and orphan drug regulatory affairs strategy. As former Director of the Office of Orphan Product Development (OOPD) at FDA, between 2007 – 2011, Dr. Cote led the agency’s efforts in implementing the Orphan Drug Act and personally signed decisions on 1400+ orphan drug designation applications. Dr. Coté received a bachelor’s degree from Syracuse University, his medical doctorate from the Howard University College of Medicine and a Master of Public Health (MPH) from the Harvard School of Public Health.
Regulatory Affairs Lead
Regulatory Affairs Lead
Preeti brings over 12 years of experience in Translational Medicine across preclinical and clinical sectors. She is excited about the rapid and novel advances defining therapeutics. She received a doctorate in cell biology and pathology from Columbia University and went on to consulting, providing subject matter expertise towards tailored therapeutics across cardiometabolic, neurodegenerative, and oncological fields. She has worked with a diverse array of clients and now applies her background to rare disease profiles.
Regulatory Affairs Lead
Regulatory Affairs Lead
Ishani has a PhD in neuroscience and an MS in biomedical engineering. She has extensive experience in medical writing and scientific communication, which she now brings to the regulatory affairs team at Only Orphans Cote.
Business Development Lead
Business Development Lead
As Business Development Lead at Only Orphans Cote, Tina leverages her expertise in sales, digital marketing, and multilingual communication to drive business growth across the U.S. and Asia. She manages client relationships, develops tailored proposals for regulatory consulting services, and leads strategic outreach initiatives.
Business Development Lead
Business Development Lead
Eric graduated from the University of Colorado class of 2020 with a bachelor’s degree in communication. His background is primarily focused on business development with experience in the consulting industry.
Chief of Staff
Chief of Staff
Dina Elnaggar MD, MA, MSc brings more than 25 years of experience in the fields of human development and strategic communications in multinational organizations. Prior to joining OOC as Chief of Staff, she worked full time as a Communications and Stakeholder Engagement Team Lead at the World Bank. In her current role as Chief of Staff, she is responsible for managing work culture while supporting corporate processes and team management.
Headquartered in Cambridge, Massachusetts, with wholly owned subsidiaries in Ireland and the UK, Only Orphans Cote guides biotech and pharma clients across the world through FDA and EMA orphan drug designation pathways, including gene and cell therapy programs.
January 11-13, San Francisco, CA
January 11-15, San Francisco, CA
March 23-25, National Harbor, MD
April 5-7, Lyon, France
June 7-10, Philadelphia, PA
Late October, Stockholm, Sweden
Dr. Cote is the primary point of contact for every client. He is well supported by a team of business development associates and regulatory affairs associates who manage the administration of meetings and contracts, and the drafting of manuscripts, respectively. However, all critical work is overseen directly by Dr. Cote. Every word submitted is his responsibility, every meeting is with him, and your success is placed in his hands. Clients can count on his personal attention and accountability throughout the process.
In the conduct of two consultancies over 8 years, Dr. Cote has personally written over 900 orphan designation applications, certainly more than anyone else on the planet.
No. Programs come to us from biotechs and pharma companies well beyond the U.S. The same FDA and EMA expertise applies wherever your program is based.
Yes. Between 2012 and 2017, Dr. Cote personally submitted more European orphan drug designation applications than any single European entity. This is in addition to years of direct collaboration with the EMA's Committee on Orphan Medicinal Products while he was still at the FDA. That depth carries into every EMA program Only Orphans Cote takes on today.